Tag: TCT 2017

TCT 2017: The HREVS study provides supportive evidence for the hybrid...

The HREVS (Hybrid coronary revascularisation vs. standard) trial found that there was no significant difference between percutaneous coronary intervention (PCI), coronary artery bypass grafting...

TCT 2017: FAME 2 provides support for PCI in stable disease...

Following ORBITA, which indicated percutaneous coronary intervention (PCI) did not provide benefit over a sham procedure in patients with stable coronary artery disease, the...

TCT 2017: Advances in device technology needed to improve outcomes with...

Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott) is substantially reduced when the device is...

Interventional cardiology in the Twitterverse

The past few years has witnessed increasing clinician engagement with social media platforms, including Twitter (which, overall, has 300 million active users). Well-known “Tweeters”...

TCT 2017: TMVI in mitral ring is a reasonable alternative for...

Data from the MITRAL (Mitral Implantation of Transcatheter valves) study indicate that transeptal transcatheter mitral valve implantation (TMVI), with a Sapien 3 device (Edwards...

A bold new study could alter the orbit of elective PCI

The ORBITA (Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable disease) study, recently presented at 2017 Transcatheter Cardiovascular Therapeutics (TCT)...

TCT 2017: Sham-controlled trial raises doubts about benefit of angiography-guided PCI...

ORBITA (Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable disease)—the first-ever sham controlled trial of percutaneous coronary intervention (PCI)—indicates that...

TCT 2017: Study challenges recommendations on the management of cardiogenic shock

Advice on percutaneous coronary intervention (PCI) strategies for patients with acute myocardial infarction complicated by cardiogenic shock may need to be revised after the...

TCT 2017: Elixir reveals new drug-eluting stent

Elixir Medical unveiled for the first time its novel stent technology—Dynamx—at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). A...

TCT 2017: Pooled analysis of Magmaris studies continue to show no...

Data presented during the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA), according to a press release, provide further evidence of...

TCT 2017: Next-generation FFR system launched

Acist has announced the global launch of its RXi Mini system—the next-generation system of its RXi Rapid Exchange fractional flow reserve (FFR) system. The...

TCT 2017: No advantage with extending dual antiplatelet therapy beyond six...

The primary results from the DAPT-STEMI trial suggest that 12-month dual antiplatelet therapy (DAPT) is not superior to six-month DAPT in patients who have...

TCT 2017: Fantom bioresorbable scaffold continues to show positive outcomes at...

The Fantom bioresorbable scaffold (Reva Medical) shows continued positive clinical outcomes according to an interim data set from the FANTOM II clinical trial, which...

TCT 2017: Two studies support feasibility of transcatheter mitral valve implantation

Early experiences with two transcatheter mitral valve implantation (TMVI) devices—Intrepid (Medtronic) and the Tendyne mitral valve (Abbott)—indicate that TMVI may be a safe and...

TCT 2017: No role for bare metal stents to reduce duration...

Olivier Varenne (Hôpital Cochin, Assistance Publique—Hôpitaux De Paris, Paris, France) reported that the strategy of using bare metal stents to enable a shorter duration...

TCT 2017: TAVI “should be the preferred strategy” for patients at...

David Cohen (Saint Luke’s Mid America Heart Institute, Kansas City, USA) has suggested that, on basis of both clinical and economic considerations, transcatheter aortic...

TCT 2017: New data for CoreValve Evolut further support its use...

New clinical research, presented today at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October- 2 November, Denver, USA), support the positive clinical performance...

TCT 2017: Combo dual-therapy stent is non-inferior to Xience at one...

New results from the HARMONEE Japan/US registration trial, which were presented yesterday at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October – 2...

TCT 2017: Data for novel cardiac imaging technology unveiled

New data from the ongoing CADLAD (Coronary artery disease learning and algorithm development) study will be presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT)...

TCT 2017: AI-driven cardiac ultrasound company to give two presentations

Bay Labs, a medical technology company developing an artificial intelligence in cardiovascular imaging, has announced that its chief medical officer Randolph P Martin (Emory...

Cobra PzF nano-coated stent now being studied with 14-day DAPT in...

The US FDA has approved the expansion of CeloNova’s ongoing clinical trial of its proprietary Cobra PzF nano-coated stent to enable the use of...

TCT 2017: Boston Scientific reveals presentations at conference

Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). For example,...

TCT 2017: Elixir Medical to reveal “a game-changing metallic drug-eluting stent...

Elixir Medical has revealed details of its programme and activities during the 2017 meeting of the transcatheter cardiovascular therapeutics (TCT; 29 October–2 November, Denver,...

TCT 2017: Alec Vahanian to receive the Master Clinical Operator award

The Geoffrey O. Hartzler Master Clinical Operator Award will be presented to Alec Vahanian (Cardiology Department, University Paris Diderot, Bichat Hospital, AP-HP, Paris, France)...

TCT 2017: Cardiovascular Research Foundation announces late-breaking trials and first-report investigations

The Cardiovascular Research Foundation (CRF) has release details of the 12 late-breaking trials and 16 first report investigations that are to be presented at...